[go: up one dir, main page]

NO984343D0 - Preparat inneholdende en kombinasjon av 5-metylisoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluor-metylfenyl)2-cyano-3-hydroksykrotin - Google Patents

Preparat inneholdende en kombinasjon av 5-metylisoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluor-metylfenyl)2-cyano-3-hydroksykrotin

Info

Publication number
NO984343D0
NO984343D0 NO984343A NO984343A NO984343D0 NO 984343 D0 NO984343 D0 NO 984343D0 NO 984343 A NO984343 A NO 984343A NO 984343 A NO984343 A NO 984343A NO 984343 D0 NO984343 D0 NO 984343D0
Authority
NO
Norway
Prior art keywords
trifluoromethylphenyl
trifluoromethyl
cyano
hydroxycrotin
methylisoxazole
Prior art date
Application number
NO984343A
Other languages
English (en)
Other versions
NO984343L (no
NO315595B1 (no
Inventor
Robert Bartlett
Johann Then
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7788856&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO984343(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO984343D0 publication Critical patent/NO984343D0/no
Publication of NO984343L publication Critical patent/NO984343L/no
Publication of NO315595B1 publication Critical patent/NO315595B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO19984343A 1996-03-20 1998-09-18 Preparat inneholdende en kombinasjon av 5-metylisoksazol-4- karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluormetylfenyl)2-cyano-3-hydroksykrotin NO315595B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19610955A DE19610955A1 (de) 1996-03-20 1996-03-20 Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
PCT/EP1997/001167 WO1997034600A1 (de) 1996-03-20 1997-03-07 Kombinationspräparat, enthaltend 5-methylisoxazol-4-carbonsäure-(4-trifluormethyl)-anilid und n-(4-trifluormethylphenyl)-2-cyan-3-hydroxycrotonsäureamid

Publications (3)

Publication Number Publication Date
NO984343D0 true NO984343D0 (no) 1998-09-18
NO984343L NO984343L (no) 1998-09-18
NO315595B1 NO315595B1 (no) 2003-09-29

Family

ID=7788856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19984343A NO315595B1 (no) 1996-03-20 1998-09-18 Preparat inneholdende en kombinasjon av 5-metylisoksazol-4- karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluormetylfenyl)2-cyano-3-hydroksykrotin

Country Status (22)

Country Link
US (1) US7071222B2 (no)
EP (1) EP0896537B1 (no)
JP (1) JP4206131B2 (no)
KR (1) KR100464693B1 (no)
CN (1) CN1141095C (no)
AT (1) ATE183393T1 (no)
AU (1) AU705692B2 (no)
BG (1) BG64189B1 (no)
BR (1) BR9708108A (no)
CY (1) CY2209B1 (no)
CZ (1) CZ289446B6 (no)
DE (2) DE19610955A1 (no)
ES (1) ES2137055T3 (no)
GR (1) GR3031637T3 (no)
HU (1) HU226677B1 (no)
NO (1) NO315595B1 (no)
NZ (1) NZ331933A (no)
PL (1) PL188052B1 (no)
RU (1) RU2198655C2 (no)
TR (1) TR199801862T2 (no)
UA (1) UA46103C2 (no)
WO (1) WO1997034600A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
DE19960443C2 (de) 1999-12-15 2002-05-08 Aventis Pharma Gmbh Verfahren zur Auffindung von Nukleotidsyntheseinhibitoren mit weniger Nebenwirkungen
CZ20022000A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceuticals Industries Ltd. Způsoby přípravy a nová krystalická forma leflunomidu
DE10112924A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt 1-Butansäurederivate, pharmazeutische Zusammensetzungen enthaltend solche Derivate und Verwendungen solcher Derivate
DE10112925A1 (de) * 2001-03-13 2002-10-02 Erich Eigenbrodt Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase
CA2441088A1 (en) * 2001-03-13 2002-09-19 Protagen Ag 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof
GB0123571D0 (en) 2001-04-05 2001-11-21 Aventis Pharm Prod Inc Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE60330391D1 (de) 2002-12-23 2010-01-14 4Sc Ag Cycloalken-dicarbonsäure-verbindungen als entzündungshemmende, immunmodulatorische und antiproliferative mittel
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
EP2100881A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Pyrimidyl- or pyridinylaminobenzoic acid derivatives
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) * 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2239256A1 (en) 2009-03-13 2010-10-13 Almirall, S.A. Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
US8686048B2 (en) 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
UA108760C2 (uk) 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
EP2444086A1 (en) 2010-10-22 2012-04-25 Almirall, S.A. Combinations comprising DHODH inhibitors and COX inhibitors
EP2672963A4 (en) 2011-02-08 2015-06-24 Childrens Medical Center METHOD FOR THE TREATMENT OF MELANOMA
CN103755592A (zh) * 2013-12-30 2014-04-30 镇江圣安医药有限公司 (2z)-氰基-3-羟基-n-[4-(三氟甲基)苯基]-2-丁烯酰胺的衍生物及其应用
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
EP3765439B1 (en) 2018-03-16 2024-05-01 Immunic AG Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CA3176008A1 (en) 2020-04-21 2021-10-28 Manfred Groppel Vidofludimus for use in the treatment or prevention of viral diseases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3534440A1 (de) * 1985-09-27 1987-04-02 Hoechst Ag Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en) 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
EP0527736B1 (de) 1990-05-18 1997-04-16 Hoechst Aktiengesellschaft Isoxazol-4-carbonsäureamide und hydroxyalkyliden-cyanessigsäureamide, diese verbindungen enthaltende arzneimittel und deren verwendung
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5519042A (en) 1994-01-13 1996-05-21 Hoechst Aktiengesellschaft Method of treating hyperproliferative vascular disease
DE19908527C2 (de) * 1999-02-26 2001-08-30 Aventis Pharma Gmbh Verfahren zur Kristallisation von N-(4-Trifluormethylphenyl)-5-methyl-isoxazol-4-carboxamid

Also Published As

Publication number Publication date
EP0896537A1 (de) 1999-02-17
JP4206131B2 (ja) 2009-01-07
CY2209B1 (en) 2002-11-08
NO984343L (no) 1998-09-18
CN1213302A (zh) 1999-04-07
CN1141095C (zh) 2004-03-10
BG102697A (en) 1999-09-30
KR20000064757A (ko) 2000-11-06
US7071222B2 (en) 2006-07-04
PL328998A1 (en) 1999-03-01
UA46103C2 (uk) 2002-05-15
HU226677B1 (en) 2009-06-29
PL188052B1 (pl) 2004-12-31
HUP9902130A3 (en) 2001-01-29
BG64189B1 (bg) 2004-04-30
HUP9902130A2 (hu) 1999-11-29
WO1997034600A1 (de) 1997-09-25
GR3031637T3 (en) 2000-02-29
NZ331933A (en) 2000-06-23
DE59700356D1 (en) 1999-09-23
JP2000510440A (ja) 2000-08-15
US20020006945A1 (en) 2002-01-17
AU705692B2 (en) 1999-05-27
NO315595B1 (no) 2003-09-29
AU1926197A (en) 1997-10-10
CZ289446B6 (cs) 2002-01-16
EP0896537B1 (de) 1999-08-18
CZ298598A3 (cs) 1998-12-16
BR9708108A (pt) 1999-07-27
HK1018742A1 (en) 2000-01-07
ES2137055T3 (es) 1999-12-01
RU2198655C2 (ru) 2003-02-20
TR199801862T2 (xx) 1998-12-21
KR100464693B1 (ko) 2005-04-19
DE19610955A1 (de) 1997-09-25
ATE183393T1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
NO984343D0 (no) Preparat inneholdende en kombinasjon av 5-metylisoksazol-4-karboksylsyre-(4-trifluormetyl)-anilid og N-(4-trifluor-metylfenyl)2-cyano-3-hydroksykrotin
FR2744442B1 (fr) Preparation du 1,1,1,3,3-pentachlorobutane et du 1,1,1,3,3,-pentafluorobutane
NO996433L (no) Nye formuleringer av legemidler, fremgangsmåter for fremstilling derav og fremgangsmåter for anvendelse derav
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
NO972972L (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO994613D0 (no) Fremgangsmaate og preparat til behandling av sövn-apne
NO986089D0 (no) Metoder og preparater for behandling av tumorer, tumorrelaterte sykdommer o
IL125671A0 (en) Crystal form of n-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide
NO995431D0 (no) Substituerte 3,3-diamino-2-propennitriler, deres fremstilling og anvendelse
PL327171A1 (en) Novel derivatives of phenyl amine, method of obtaining them and their application as therapeutic agents
NO994505L (no) Forbedret fremgangsmåte for fremstilling av tiazolidindioner og nye tiazolidindioner
NO326826B1 (no) Alfa-aminosyreamider, fremstilling og terapeutisk anvendelse derav
NO984624D0 (no) Nye furan-diarylmetyliden-derivater, fremgangsmÕte for deres fremstilling og terapeutiske anvendelser derav
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer
TR199801184T2 (xx) Analjezik tesirli yeni bile�ikler.
NO982105D0 (no) Nye mellomprodukter og deres anvendelse for fremstilling av N,N'-broslÕtte bisindolylmaleimider
NO921086L (no) Fremgangsmaate for fremstilling og anvendelse av substituerte 2',3'-didesoksy-5-trifluormetyluridiner
JPS6416755A (en) Manufacture of n-(3',4'-dimethoxycinnamoyl)-aniline derivative
CA2249348A1 (en) Preparation containing a combination of 5-methylisoxazole-4-carboxylic acid-(4-trifluoromethyl)-anilide and n-(4-trifluoromethylphenyl)2-cyano-3-hydroxycrotonic acid amide
EE03796B1 (et) 3,5-difluoropüridiinid, nende valmistamismeetod, herbitsiidne kompositsioon, nende kasutamine ja vaheühend
ITMI920525A1 (it) Derivato dell'acido l-tiazolidin-4-carbossilico, sua preparazione e suo impiego terapeutico
DE69703422D1 (de) Herstellung von Aminophenolen
NO962782D0 (no) Farmasöytiske formuleringer omfattende polytiourea, og metode for anvendelse derav
AU1479800A (en) Procedure for synthesis of N-(2(((5-((dialkilamino) methyl)-2- furanyl) methyl)thyo) ethyl)-N'- alkyl-2-nitro1,1 alkenediamines and their hydrochlorides
EP1671630A3 (en) L-Arginine based formulations for treating diseases and methods of using the same

Legal Events

Date Code Title Description
MK1K Patent expired